Physician
Masoud Khorsand- Sahbaie MD P a
Masoud Khorsand- Sahbaie MD P a was paid $8.06M by Medicaid between Jan 2018 and Dec 2024, across 128 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 49% of everything it billed.
33Billing provider infoMASOUD KHORSAND- SAHBAIE MD P A
ROSWELL, NM 88201
ROSWELL, NM 88201
33aNPI1932187044assigned 01/09/2006
33bProvider typeHematology & Oncology Physician
28Total paid$8.06M
24GClaims277,802
24DCodes billed128
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Hematology & Oncology Physician providers in New Mexico
Rank by total paid#1 of 8
Median peer was paid$509K
This provider vs. median16×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 33,599 | $897K | |
| 2019 | 41,826 | $1.14M | |
| 2020 | 43,050 | $1.21M | |
| 2021 | 44,217 | $988K | |
| 2022 | 39,459 | $935K | |
| 2023 | 44,385 | $1.49M | |
| 2024incomplete | 31,266 | $1.40M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 49% | 58,867 | 53,485 | $3.92M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 9.8% | 17,496 | 15,914 | $788K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 6.0% | 6,604 | 4,797 | $487K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 5.8% | 3,926 | 3,797 | $468K |
| 80053 | Comprehensive metabolic panel | 2.8% | 22,326 | 19,484 | $222K |
| 80050 | General health panel | 2.3% | 3,648 | 3,609 | $186K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.1% | 22,903 | 19,172 | $169K |
| 36415 | Collection of venous blood by venipuncture | 2.1% | 39,245 | 34,105 | $167K |
| 99205 | Prolong outpt/office vis | 1.6% | 856 | 837 | $128K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.5% | 1,233 | 1,169 | $124K |
| 80061 | Lipid panel | 1.5% | 9,444 | 9,193 | $119K |
| 78815 | Positron emission tomography (PET) for limited area imaging | 1.4% | 81 | 76 | $111K |
116 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.3% | 4,352 | $101K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,723 | $77K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,933 | $62K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 565 | $60K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 669 | $50K |
| 84439 | <1% | 4,642 | $41K | |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | <1% | 12 | $41K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,234 | $35K |
| 99442 | <1% | 484 | $35K | |
| 86235 | <1% | 330 | $35K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 49 | $31K |
| 83615 | <1% | 5,108 | $30K | |
| 82728 | <1% | 2,397 | $30K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,736 | $30K |
| 86140 | <1% | 5,630 | $28K | |
| 86480 | <1% | 315 | $21K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 20 | $19K |
| 83550 | <1% | 2,187 | $17K | |
| 80074 | <1% | 337 | $17K | |
| 93000 | <1% | 1,818 | $17K | |
| 86147 | <1% | 291 | $16K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 170 | $16K |
| 99441 | <1% | 429 | $16K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 295 | $15K |
| 99443 | <1% | 172 | $15K | |
| 86146 | <1% | 254 | $15K | |
| 83540 | <1% | 2,214 | $13K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,511 | $13K |
| 20610 | <1% | 257 | $12K | |
| 82570 | <1% | 2,211 | $11K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 28 | $11K |
| 81001 | <1% | 3,571 | $10K | |
| 84481 | <1% | 594 | $10K | |
| 73620 | <1% | 584 | $10K | |
| 82043 | <1% | 1,705 | $9K | |
| J3490 | Unclassified drugs | <1% | 5,332 | $9K |
| 73630 | <1% | 392 | $9K | |
| 73120 | <1% | 577 | $9K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,208 | $9K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,836 | $8K |
| 86160 | <1% | 440 | $8K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 383 | $8K |
| 36591 | <1% | 670 | $7K | |
| 83970 | <1% | 137 | $7K | |
| 85652 | <1% | 2,309 | $6K | |
| 86200 | <1% | 424 | $6K | |
| 96415 | <1% | 191 | $5K | |
| 82607 | <1% | 334 | $5K | |
| 90686 | <1% | 332 | $5K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 479 | $5K |
| 82378 | <1% | 261 | $4K | |
| 84550 | <1% | 1,161 | $4K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 118 | $4K |
| 74178 | <1% | 29 | $4K | |
| 85045 | <1% | 1,161 | $4K | |
| 86225 | <1% | 257 | $4K | |
| 86038 | <1% | 284 | $4K | |
| 96417 | <1% | 50 | $4K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 5,092 | $4K |
| 90674 | <1% | 217 | $4K | |
| 90670 | <1% | 14 | $3K | |
| 83516 | <1% | 221 | $3K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 63 | $3K |
| 73130 | <1% | 66 | $2K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 57 | $2K |
| 81025 | <1% | 274 | $2K | |
| 93458 | <1% | 13 | $2K | |
| 86431 | <1% | 381 | $2K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 14 | $2K |
| 99422 | <1% | 32 | $2K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 155 | $2K |
| 71270 | <1% | 12 | $2K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 54 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,406 | $2K |
| 20604 | <1% | 28 | $2K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 73 | $1K |
| 83735 | <1% | 248 | $1K | |
| 76881 | <1% | 18 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,063 | $1K |
| 80069 | <1% | 163 | $1K | |
| 80076 | <1% | 131 | $1K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 17 | $966.51 |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 13 | $919.90 |
| 99423 | <1% | 12 | $777.32 | |
| 85613 | <1% | 78 | $769.91 | |
| 84156 | <1% | 214 | $742.77 | |
| 76942 | <1% | 13 | $740.27 | |
| 83520 | <1% | 35 | $691.34 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 138 | $687.89 |
| 93015 | <1% | 12 | $674.95 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 177 | $674.50 |
| 82172 | <1% | 31 | $655.67 | |
| 82550 | <1% | 74 | $596.91 | |
| 20550 | <1% | 13 | $591.65 | |
| 82746 | <1% | 37 | $591.33 | |
| 96523 | <1% | 46 | $553.11 | |
| 82565 | <1% | 96 | $494.58 | |
| 85730 | <1% | 65 | $393.42 | |
| 82248 | <1% | 81 | $387.23 | |
| 86039 | <1% | 35 | $379.50 | |
| 85610 | <1% | 78 | $321.70 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 15 | $236.63 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 112 | $147.98 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 52 | $136.25 |
| 84100 | <1% | 33 | $122.69 | |
| 90756 | <1% | 14 | $122.09 | |
| 84436 | <1% | 18 | $121.24 | |
| 84479 | <1% | 18 | $107.52 | |
| 87088 | <1% | 12 | $96.35 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 12 | $96.17 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 12 | $56.08 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 15 | $9.13 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 421 | $4.64 |
| 4004F | 0% | 56 | $0.00 | |
| G9225 | Foot exam was not performed, reason not given | 0% | 42 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 89 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKHORSAND-SAHBAIE, MASOUD (OWNER)